335 related articles for article (PubMed ID: 35453938)
1. Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.
Cutolo C; Dell'Aversana F; Fusco R; Grazzini G; Chiti G; Simonetti I; Bruno F; Palumbo P; Pierpaoli L; Valeri T; Izzo F; Giovagnoni A; Grassi R; Miele V; Barile A; Granata V
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453938
[TBL] [Abstract][Full Text] [Related]
2. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
3. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
[TBL] [Abstract][Full Text] [Related]
6. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
7. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
[TBL] [Abstract][Full Text] [Related]
10. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives.
Eschrich J; Kobus Z; Geisel D; Halskov S; Roßner F; Roderburg C; Mohr R; Tacke F
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612297
[TBL] [Abstract][Full Text] [Related]
11. Combined hepatocellular-cholangiocarcinoma: An update.
Beaufrère A; Calderaro J; Paradis V
J Hepatol; 2021 May; 74(5):1212-1224. PubMed ID: 33545267
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
[TBL] [Abstract][Full Text] [Related]
14. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning.
Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V
JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Assessment of Hypovascular Component in Arterial Phase to Help the Discrimination of Combined Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma.
Yang X; Chang J; Li R; Qi Y; Zeng X; Wang W; Li H
J Hepatocell Carcinoma; 2023; 10():113-122. PubMed ID: 36727035
[TBL] [Abstract][Full Text] [Related]
16. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
17. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
Gigante E; Ronot M; Bertin C; Ciolina M; Bouattour M; Dondero F; Cauchy F; Soubrane O; Vilgrain V; Paradis V
Liver Int; 2019 Dec; 39(12):2386-2396. PubMed ID: 31544304
[TBL] [Abstract][Full Text] [Related]
18. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
[TBL] [Abstract][Full Text] [Related]
19. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
Gigante E; Hobeika C; Le Bail B; Paradis V; Tougeron D; Lequoy M; Bouattour M; Blanc JF; Ganne-Carrié N; Tran H; Hollande C; Allaire M; Amaddeo G; Regnault H; Vigneron P; Ronot M; Elkrief L; Verset G; Trepo E; Zaanan A; Ziol M; Ningarhari M; Calderaro J; Edeline J; Nault JC
Liver Cancer; 2022 Sep; 11(5):460-473. PubMed ID: 36158591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
